Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LaeknaFRA:4U4 +2.21%19 FCF Margin % is -18.01% as of Dec. 2025. GuruFocus rates FRA:4U4 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 957 Biotechnology companies, Laekna ranks worse than 51.31% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Laekna's Free Cash Flow for the
six
months ended in Dec. 2025 was €-2.33 Mil. Laekna's Revenue for the
six
months ended in Dec. 2025 was €12.94 Mil. Therefore, Laekna's FCF Margin % for the quarter that ended in Dec. 2025 was -18.01%.
The historical data trend for Laekna's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4U4 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Laekna's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laekna FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Laekna's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Laekna's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laekna (FRA:4U4) has a FCF Margin % of -18.01% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Laekna and its competitors. According to the industry distribution chart, Laekna ranks #491 out of 957 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Laekna's FCF Margin % too high?
Laekna's current FCF Margin % is -18.01%. Based on the distribution chart, Laekna ranks #491 out of 957 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Laekna has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Laekna's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Laekna ranks #491 out of 957 companies for FCF Margin %. This places Laekna in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Laekna and its competitors. Laekna's current FCF Margin % is -18.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laekna stock overvalued right now?
Laekna (FRA:4U4) has a current FCF Margin % of -18.01%. The current FCF Margin % is -18.01%. Laekna's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Laekna (FRA:4U4), the current FCF Margin % is -18.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers. Laekna has two Core Products and other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer.
19GF Score
Get the complete analysis for FRA:4U4
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4U4 has been successfully added to your 
